Jasper Therapeutics Files Form 8-K: Key Details for Investors
Jasper Therapeutics, Inc. (NASDAQ: JSPR) has filed a Form 8-K current report with the U.S. Securities and Exchange Commission, dated July 31, 2026. This filing provides an update on company governance and securities registration details, which are crucial for shareholders and potential investors to review. Below are the key highlights and important information extracted from the filing.
Key Points from the Form 8-K Filing
- Company Name & Address: Jasper Therapeutics, Inc., headquartered at 2200 Bridge Parkway, Suite #102, Redwood City, CA 94065.
- Trading Symbols: The company’s Voting Common Stock is traded under the symbol JSPR and its Redeemable Warrants (each ten warrants exercisable for one share of Voting Common Stock at an exercise price of \$115.00) are traded under the symbol JSPRW on the Nasdaq Stock Market LLC.
- Emerging Growth Company Status: Jasper Therapeutics has indicated it is an emerging growth company as defined under Rule 405 of the Securities Act of 1933 and Rule 12b-2 of the Securities Exchange Act of 1934. This status allows the company to take advantage of reduced reporting requirements and extended compliance periods for new or revised accounting standards.
- Transition Period Election: The company has not elected to use the extended transition period for complying with any new or revised financial accounting standards under Section 13(a) of the Exchange Act.
- Securities Registered:
- Voting Common Stock, par value \$0.0001 per share (Symbol: JSPR)
- Redeemable Warrants, each ten warrants exercisable for one share of Voting Common Stock at \$115.00 (Symbol: JSPRW)
Both securities are registered and traded on Nasdaq.
- Filing Compliance: The report confirms that Jasper Therapeutics is not simultaneously satisfying the filing obligation under Rules 425, 14a-12, 14d-2(b), or 13e-4(c) (i.e., no written communications, solicitation materials, or pre-commencement tender offer communications included).
- Corporate Change: The company was formerly known as Amplitude Healthcare Acquisition Corp, with a name change effective September 12, 2019.
Important Shareholder Information & Potential Price Sensitivity
- Emerging Growth Company Status: Investors should note that Jasper’s status as an emerging growth company may impact the company’s financial disclosures and compliance obligations. This status can be favorable for the company as it allows reduced costs and less stringent regulatory requirements, but it can also mean less financial transparency compared to larger, established firms.
- Redeemable Warrants: The presence of redeemable warrants (JSPRW), each ten exercisable for one share of Voting Common Stock at an exercise price of \$115.00, could be relevant for future capital structure changes or dilution risks. If exercised, these warrants may increase the outstanding shares, potentially affecting share value.
- No Tender Offer or Solicitation Material: The filing confirms there are no ongoing tender offers, issuer tender offers, or solicitation materials, which means there are no imminent corporate actions (such as buybacks or mergers) that may affect stock price.
- Corporate Name Change: While historical, the change from Amplitude Healthcare Acquisition Corp to Jasper Therapeutics may be relevant for investors tracking company history and prior filings.
Summary and Investor Takeaway
The July 31, 2026, Form 8-K filing for Jasper Therapeutics is primarily administrative, confirming the registration of securities and the company’s compliance status. The most notable detail for investors is the company’s designation as an emerging growth company and the existence of substantial redeemable warrants, which could, if exercised, lead to dilution of common stock. There are no tender offers, mergers, or other corporate actions in progress that would directly affect share price at this time.
There are no new material events disclosed in this filing that would immediately impact the share price of JSPR or JSPRW.
Disclaimer: This article is a summary of Jasper Therapeutics’ Form 8-K SEC filing dated July 31, 2026. It does not constitute investment advice. Investors should consult the official SEC filings and their financial advisors before making any investment decisions.
